Mersana Therapeutics Inc

Mersana Therapeutics — Investor Presentation (August 2025)

35 slides from Mersana Therapeutics's investor presentation, Aug 13, 2025

  1. Slide 1: Corporate Presentation

    Corporate Presentation August 13, 2025

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation contains “forward-looking” statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “g

  3. Slide 3: Corporate Overview

    Corporate Overview • Encouraging and unique clinical activity observed in post-topo-1 TNBC, an indication with high unmet need, with differentiated safety and tolerability Advancing Emi-Le to • >40 patients enrolled in expansion in post-topo-1 TNBC at two doses; plan to present initial expansion Add

  4. Slide 4: Focused on Overcoming Today's ADC Limitations

    Focused on Overcoming Today's ADC Limitations ADCs TODAY THE MERSANA OPPORTUNITY First-Generation ADCs Limited by Safety Establish the Best-In-Class Anti-Tubulin Platform First wave of anti-tubulins dose limited by platform toxicities (neuropathy, neutropenia, ocular toxicity, etc.) Dolasynthen desi

  5. Slide 5: Mersana's ADC Pipeline

    Mersana’s ADC Pipeline Platform ADC Program Target Indication(s) Preclinical P1 Dose Escalation P1 Dose Expansion Dolasynthen Emi-Le (XMT-1660) B7-H4 Multiple Solid Tumors Immunosynthen XMT-2056 Novel HER2 Epitope Multiple Solid Tumors * Collaborators Dolasynthen Undisclosed Undisclosed Immunosynthe

  6. Slide 6: Mersana's Next-Generation ADC Platforms

    Mersana’s Next-Generation ADC Platforms Two distinct and proprietary ADC product engines Dolasynthen Immunosynthen • Next-generation cytotoxic platform with customizable • Observed to be a potent stimulator of the innate DAR designed for enhanced PK and tumor delivery immune system in the clinic • E

  7. Slide 7: Dolasynthen

    Dolasynthen Mersana’s Next-Generation Cytotoxic ADC Platform ADC, antibody-drug conjugate

  8. Slide 8: Dolasynthen: A Differentiated Cytotoxic ADC Platform

    Dolasynthen: A Differentiated Cytotoxic ADC Platform Designed by Leveraging Clinical Learnings Site-specific bioconjugation creates fully homogeneous ADCs using a variety of approaches DAR multiplier matches the optimal DAR to target Hydrophilicity enhancer and charge balance allows for antibody-lik

  9. Slide 9: Emiltatug Ledadotin (Emi-Le; XMT-1660)

    Emiltatug Ledadotin (Emi-Le; XMT-1660) Platform: Dolasynthen Target: B7-H4 DAR: 6 Status: Phase 1 dose expansion ongoing in patients with TNBC who have received 1-4 prior lines of therapy, including at least 1 prior topo-1 ADC DAR, drug-to-antibody ratio; TNBC, triple-negative breast cancer; topo-1,

  10. Slide 10: Background on B7-H4 and Emi-Le

    Background on B7-H4 and Emi-Le B7-H4 Emi-Le • Clinically validated target highly expressed in • Novel ADC design: Homogeneous DAR 6 TNBC, HR+BC, endometrial cancer, ovarian Dolasynthen ADC cancer, ACC-1; limited healthy tissue • Two FDA Fast Track designations granted expression for the treatment of

  11. Slide 11: Significant and Growing Unmet Need in Relapsed/Refractory TNBC

    Significant and Growing Unmet Need in Relapsed/Refractory TNBC Global relapsed/refractory TNBC market projected to exceed $1 billion annually starting in 20251 Recent positive Phase 3 results2 for topo-1 ADCs in front-line setting may substantially expand post-topo-1 TNBC patient population ORR of 5

  12. Slide 12: Increasing Real-World Data Suggest Topo-1 Payload Resistance Greatly Reduces Clinical Benefit

    Increasing Real-World Data Suggest Topo-1 Payload Resistance Greatly Reduces Clinical Benefit Outcomes Data for Trastuzumab PFS Data for Patients Receiving Two Deruxtecan Patients With / Without Topo-1 ADC Treatment Lines Prior Sacituzumab Govitecan (HR+/HER2-Low)2 (TNBC)1 1. Tarantino et al. ASCO 2

  13. Slide 13: Emi-Le: Well Positioned in the B7-H4 Landscape

    Emi-Le: Well Positioned in the B7-H4 Landscape Clinical-Stage B7-H4 ADC Candidates Drug-to- First Patient Asset Company Linker Payload Conjugation Antibody Dosed in Ratio Phase 1 Active post- emiltatug ledadotin Cleavable Anti-Tubulin topo-1 ADCs Mersana Site Specific DAR 6 Q3 2022 (Emi-Le; XMT-1660

  14. Slide 14: Emi-Le Clinical Data from Phase 1 Dose Escalation and Backfill Cohorts

    Emi-Le Clinical Data from Phase 1 Dose Escalation and Backfill Cohorts

  15. Slide 15: Emi-Le Phase 1 Dose Escalation and Expansion

    Emi-Le Phase 1 Dose Escalation and Expansion March 8,2025 data cut-off Dose Escalation and Backfill Cohorts Ongoing Dose Expansion in TNBC Key Enrollment Criteria: 76.2 – 115.0 High Dose Key Enrollment Criteria: mg/m2 Range* (n=42) • atients ≥18 years old • Advanced or metastatic TNBC • ECOG PS 0-1

  16. Slide 16: Dose Escalation and Backfill Demographics

    Dose Escalation and Backfill Demographics Most patients had breast cancer and received at least one prior topo-1 ADC March 8,2025 data cut-off TNBC HR+/HER2- MBC Ovarian Endometrial ACC-I Total (N=63) (N=37) (N=14) (N=14) (N=13) (N=141) Median age 48 62 61 65.5 52 55 Median prior lines of therapy (r

  17. Slide 17: Safety Summary: Emi-Le Observed to be Generally Well Tolerated

    Safety Summary: Emi-Le Observed to be Generally Well Tolerated March 8,2025 data cut-off All Doses Total (N=141) TRAEs Observed (N=141) in ≥10% of patients Any treatment related adverse event (TRAE) 117 (83.0%) AST increased 17 44 Grade 3 TRAE 52 (36.9%) Proteinuria 14 40 Fatigue 33 Treatment-relate

  18. Slide 18: Clinical Activity Correlated With Both Dose and B7-H4 Expression

    Clinical Activity in Evaluable Patients Correlated With Both Dose and B7-H4 Expression March 8,2025 data cut-off Subtherapeutic Dose Range Intermediate Dose Range High Dose Range <38.1 mg/m2 38.1 - 67.4 mg/m2 ≥76.2 mg/m2 (N=14) (N=67) (N=33) 120 Best Change in Target Lesion Size from Baseline (%) 10

  19. Slide 19: Intermediate Dose Range: Encouraging Clinical Activity in B7-H4 High Tumors

    Intermediate Dose Range: Encouraging Clinical Activity in Evaluable Patients With B7-H4 High Tumors March 8,2025 data cut-off • 31% (8/26) ORR • TNBC: ORR 23% (3/13) • Endometrial: ORR 50% (2/4) • 44% (7/16) ORR in evaluable patients with ≤ prior lines of therapy • TNBC: ORR 29% (2/7) * = treatment

  20. Slide 20: Key Benchmarks in Late-Stage TNBC

    Key Benchmarks in Late-Stage TNBC Population1 Sacituzumab Govitecan Single-Agent Chemo Overall 35% 5% ASCENT Phase 3 ORR2 >3 Prior Therapies 23% 6% Overall 5.6 months 1.7 months ASCENT Phase 3 PFS3 >3 Prior Therapies 4.2 months 2.2 months Overall 12.1 months 6.7 months ASCENT Phase 3 OS2 >3 Prior Th

  21. Slide 21: Intermediate Dose Range: Clinical Activity in B7-H4 High Post-Topo-1 TNBC

    Intermediate Dose Range: Clinical Activity in Evaluable Patients With B7-H4 High Post-Topo-1 TNBC March 8,2025 data cut-off 120 Best Change in Target Lesion Size from Baseline (%) 100 • Heavily pre-treated patient Confirmed ORR: 23% (3/13) 80 population (median of four prior treatment lines) 60 40 2

  22. Slide 22: Intermediate Dose Range: Preliminary Time-to-Event Data in B7-H4 High TNBC

    Intermediate Dose Range: Preliminary Time-to-Event Data in Evaluable Patients with B7-H4 High TNBC March 8,2025 data cut-off Preliminary Progression Free Survival (PFS) Preliminary Overall Survival (OS) ≤4 prior lines: B7-H4 High vs B7-H4 Low ≤4 prior lines: B7-H4 High vs B7-H4 Low B7-H4 High: B7-H4

  23. Slide 23: High Dose Range: Preliminary Data Suggest Potential for Even Greater Clinical Activity

    High Dose Range: Preliminary Data Suggest Potential for Even Greater Clinical Activity March 8,2025 data cut-off • Clinical data suggest a dose-response relationship with Emi-Le • 7 of the 11 evaluable patients at doses >67.4 mg/m2 achieved tumor reductions of ≥30% • Believe the confirmed ORR at dos

  24. Slide 24: Enrollment Now Underway in Both Expansion Cohorts in Post-Topo-1 TNBC

    Enrollment Now Underway in Both Expansion Cohorts in Post-Topo-1 TNBC Primary Objectives: Assess safety, tolerability and preliminary antitumor activity Secondary Objectives: Assess PK and ADA Enrollment Criteria Stage 1 Stage 2 • Advanced or metastatic TNBC • 1 to 4 prior lines of treatment, includ

  25. Slide 25: Pursuing a Unique Opportunity in Post-Topo-1 TNBC with Broader Clinical Potential

    Pursuing a Unique Opportunity in Post-Topo-1 TNBC with Broader Clinical Potential Unique and Encouraging Clinical Activity in Broader Clinical Activity Differentiated Safety Post-Topo-1 TNBC, an and Potential in Other and Tolerability Profile Indication With High B7-H4-Expressing Tumors Unmet Need T

  26. Slide 26: Immunosynthen

    Immunosynthen Mersana’s STING-Agonist ADC Platform ADC, antibody-drug conjugate; STING, STimulator of INterferon Genes

  27. Slide 27: Immunosynthen: Our Proprietary STING-Agonist ADC Platform

    Immunosynthen: Our Proprietary STING-Agonist ADC Platform Designed to Localize STING Activation to Increase Potency and Decrease Systemic Toxicity Free STING Agonist Immunosynthen ADC Passive, indiscriminate Antigen-dependent, diffusion active delivery into tumor cells Active Diffusion Less efficien

  28. Slide 28: XMT-2056

    XMT-2056 Platform: Immunosynthen Target: HER2 (novel epitope) DAR: 8 Initial Cancers of Interest: HER2+ breast, gastric, colorectal and non-small-cell lung cancers DAR, drug-to-antibody ratio; HER2+, human epidermal growth factor receptor 2 positive

  29. Slide 29: XMT-2056: Our Lead Immunosynthen ADC

    XMT-2056: Our Lead Immunosynthen ADC First-in-class STING-agonist ADC targeting a novel HER2 epitope • Targets a HER2 epitope distinct from pertuzumab and trastuzumab, providing the potential for both monotherapy and combination activity • Evidence of strong preclinical activity in both HER2-high an

  30. Slide 30: A Single Dose of XMT-2056 Drives Strong Monotherapy and Combination Activity

    A Single Dose of XMT-2056 Drives Strong Monotherapy and Combination Activity in Multiple Preclinical Models Strong Activity in HER2 High XMT-2056 Enhances Activity of Anti-PD-1 Mean Tumor Volume SEM (mm3) Mean Tumor Volume SEM (mm3) 600 2000 Vehicle 1500 400 XMT-2056 surrogate 0.3 / 0.010 mg/kg 10

  31. Slide 31: XMT-2056 Phase 1 Dose Escalation Design

    XMT-2056 Phase 1 Dose Escalation Design Dose Escalation (DES) Select Enrichment Cohorts (SECs) Primary Endpoints Primary Endpoint MTD or RP2D, safety and tolerability Safety and tolerability Secondary Endpoints Secondary Endpoints ORR, DOR, DCR, PK, ADA ORR, DOR, DCR, PK, ADA Indications for DES and

  32. Slide 32: Appendix

    fWersana THERAPEUTICS Appendix

  33. Slide 33: ACC-1: An Aggressive Tumor with Poor Prognosis and High B7-H4 Expression

    ACC-1: An Aggressive Tumor with Poor Prognosis, No Approved Treatments and High B7-H4 Expression Mainly in salivary gland, also in breast, eye, trachea, Tumor Background reproductive tract US Incidence1,2 ~700 patients Median Overall Survival2 ~3 years • No systemic treatments approved • Surgery + r

  34. Slide 34: Clinical Activity in Patients with ACC-1, All Doses

    Clinical Activity in Patients with ACC-1, All Doses, Unselected for B7-H4 Expression March 8,2025 data cut-off Tumor Reduction in Evaluable Patients Preliminary PFS in all ACC-1 Patients Best Change in Target Lesion Size from Baseline (%) 40 20 20% 0 -20 -30% uPR PR -40 PR PR -60 PR -80 ORR (uPR + P

  35. Slide 35: Emi-Le ACC-1 Patient Case

    Emi-Le ACC-1 Patient Case March 8,2025 data cut-off Post Cycle 5 Baseline Cycle 2 Day 15 (post March 8 data cut-off) Left posterior lung base pleural Left posterior lung base pleural nodularity No measurable disease in the chest nodularity measures: 5.8 x 2.0 cm measures: 3.9 x 1.7 cm ACC-1, adenoid

Mersana Therapeutics — Investor Presentation (August 2025) on 6ix